CTL019 produces responses in rel/ref DLBCLJuly 14, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Combo demonstrates activity in CLL/SLL and FLJuly 11, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Nivolumab for long-term treatment of cHL after auto-HSCTJuly 7, 2017Lymphoma & Plasma Cell DisordersHodgkin LymphomaAggressive Lymphomas
FDA clears use of reagents to detect hematopoietic neoplasiaJuly 3, 2017CythemiasAnemiaLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaAggressive Lymphomas
Drug granted PRIME access as treatment for DLBCLJuly 2, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
CAR T-cell therapy shows early promise in DLBCLJune 30, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Less is more in PET-negative, advanced HLJune 28, 2017Lymphoma & Plasma Cell DisordersHodgkin LymphomaAggressive Lymphomas
CSF p-Tau predicts neurocognitive sequelae in survivors of childhood cancerJune 28, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPediatricsALLNon-Hodgkin LymphomaAggressive Lymphomas
Brentuximab meets phase 3 primary endpoint in frontline advanced HLJune 27, 2017Lymphoma & Plasma Cell DisordersHodgkin LymphomaAggressive Lymphomas
New SC rituximab formulation approved, reduces administration timeJune 24, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive Lymphomas
Chemo-free triplet produces ‘favorable’ results in advanced diseaseJune 23, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Inhibitor elicits responses in heavily pretreated FL, DLBCLJune 22, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
New frontline treatments needed for Hodgkin lymphomaJune 22, 2017Lymphoma & Plasma Cell DisordersHodgkin LymphomaAggressive Lymphomas
Biosimilar rituximab approved in EuropeJune 20, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive Lymphomas
CAR T cells plus ibrutinib induce CLL remissionsJune 17, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersAggressive Lymphomas
